Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
ScaleReady (TECH) and partners awarded four G‑Rex Grants to Children's National Hospital totaling $375,000 to support translation of cell and gene therapies into the clinic.
Grants: $100,000 to Dr. Patrick Hanley for a G‑Rex CAR‑T manufacturing process; $150,000 shared by Drs. Keller and Hanley to move VST and TAAT workflows into G‑Rex M series bioreactors; $75,000 to Dr. Amy Hont for ATTACK TAAT; $50,000 to Dr. Cruz for CAR‑modified TAAT process development.
ScaleReady reports its G‑Rex Grant Program surpassed $40M of no‑cost product commitments and launched a free LEAN Cell & Gene event series.
Bio-Techne (NASDAQ:TECH) and Saguaro Biosciences announced a distribution agreement on October 15, 2025 to expand global access to Saguaro’s non-toxic, wash-free live-cell dyes.
The partnership will use Bio-Techne’s international sales and marketing channels to distribute Saguaro products including ChromaLIVE™, NucleoLIVE™, and MortaLIVE™, targeting researchers in biotech, academia, and large pharma for cell-based assays, viability testing, and phenotypic profiling.
Bio-Techne (NASDAQ: TECH) will host a live conference call and webcast on Wednesday, November 5, 2025 at 8:00 a.m. CST to review first quarter fiscal 2026 financial results.
Live access: dial 1-800-274-8461 or 1-203-518-9814 (international) using Conference ID TECHQ1, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available starting 11:00 a.m. CST on November 5, 2025 through 11:00 p.m. CST on December 5, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160247.
Bio-Techne (NASDAQ: TECH) expanded its collaboration with Oxford Nanopore Technologies and broadened commercial rights to develop a portfolio of genetics products on Oxford Nanopore platforms.
The agreement formally extends the partnership through 2032, builds on the March 2025 launch of the AmplideX Nanopore Carrier Plus Kit, and establishes a framework to define and propose future targeted enrichment sequencing kits for screening and diagnosis of heritable genetic disorders.
The companies said the enhancement will streamline coordination on development and commercialization and support Bio-Techne's diagnostics growth strategy by accelerating innovation and portfolio planning.
Bio-Techne (NASDAQ: TECH) announced advancements in its spatial biology portfolio, featuring the RNAscope™ ISH technology and Lunaphore COMET™ platforms. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, bridging translational research and clinical applications.
The company will showcase these technologies at the National Society of Histotechnology Convention (September 26-30), featuring presentations on RNAscope's application in B-cell clonality assessment and COMET's capabilities in lymphoid malignancy profiling using a 21-plex seqIF™ panel. Bio-Techne is also advancing its partnership with Leica Biosystems, co-hosting a reception to demonstrate RNAscope assays on Leica BOND platforms.
Bio-Techne (NASDAQ: TECH) has released its 2025 Corporate Sustainability Report, highlighting significant progress in environmental stewardship and innovation. The company achieved a notable 40% reduction in Scope 1 and 2 emissions through renewable electricity adoption at its Minneapolis headquarters.
Under CEO Kim Kelderman's leadership, Bio-Techne has committed to setting science-based GHG reduction targets for validation by SBTi in 2026. The company continues to advance breakthroughs in various diseases while implementing enhanced governance measures, including new Board oversight of AI and completion of climate assessments.
The report emphasizes Bio-Techne's focus on sustainable innovation across its life sciences portfolio, particularly in cell therapy, proteomic instruments, and precision diagnostics.
CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.
Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.
ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, has awarded eight G-Rex Grants totaling nearly $2 million to California Institute for Regenerative Medicine (CIRM) Manufacturing Network program recipients. The grants support cell and gene therapy (CGT) manufacturing advancement in California.
The grants, ranging from $125,000 to $300,000, were awarded to prestigious institutions including UC San Diego, City of Hope, Stanford Medicine, USC/CHLA, UC Davis, UCSF, UCLA, and Cedars Sinai. These grants are part of ScaleReady's $40 million initiative to advance CGT development and manufacturing.
Recipients will receive exclusive support from ScaleReady's consortium of G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality control, regulatory affairs, and CGT business operations.
Bio-Techne (NASDAQ: TECH) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 10:15 AM EDT, the Baird Global Healthcare Conference on September 9 at 9:05 AM EDT, and the Morgan Stanley Global Healthcare Conference on September 10 at 10:45 AM EDT.
Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website under the IR Calendar page.
ScaleReady (NYSE:TECH) has awarded a $300,000 G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory to develop a modular CAR T-cell manufacturing platform. The grant will support optimization of key CAR-T cell manufacturing steps through Design of Experiments (DoE) evaluation.
The Gates Institute will receive early access to CellReady's G-CAR-T™, a standardized CAR-T drug product manufacturing operation. ScaleReady's G-Rex Grant Program has authorized over $40M of products to grant recipients to advance cell and gene therapy development and manufacturing.
Additionally, ScaleReady announced a new free program called LEAN Cell & Gene™, launched in partnership with Hanson Wade, aimed at improving efficiency in CGT manufacturing.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
